{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:07:21Z","timestamp":1790888841053,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clgc.2019.03.012","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T13:45:21Z","timestamp":1553694321000},"page":"e658-e663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0741-1668","authenticated-orcid":false,"given":"Mario","family":"Uccello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasnim","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haider","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajith","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Paskins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Faust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.03.012_bib1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.03.012_bib2","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.03.012_bib3","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.03.012_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.03.012_bib5","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Under-representation of patients 65 years of age or older in cancer-treatment trials","volume":"341","author":"Hutchins","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.03.012_bib6","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S1470-2045(18)30125-6","article-title":"Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology","volume":"19","author":"Kanesvaran","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.03.012_bib7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ctrv.2018.07.009","article-title":"Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma","volume":"70","author":"Atkins","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2019.03.012_bib8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.03.012_bib9","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.03.012_bib10","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.03.012_bib11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","article-title":"The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study","volume":"16","author":"Ko","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.03.012_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejca.2017.04.015","article-title":"Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre","volume":"79","author":"Matias","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.03.012_bib13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.21037\/atm.2018.04.44","article-title":"Survival outcomes for advanced kidney cancer patients in the era of targeted therapies","volume":"6","author":"Rao","year":"2018","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clgc.2019.03.012_bib14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/annonc\/mds431","article-title":"Safety and activity of sunitinib in elderly patients (\u2265 70 years) with metastatic renal cell carcinoma: a multicenter study","volume":"24","author":"Brunello","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.03.012_bib15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jgo.2014.01.001","article-title":"Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer","volume":"5","author":"De Giorgi","year":"2014","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.clgc.2019.03.012_bib16","first-page":"1","article-title":"Efficacy and safety of sunitinib in elderly patients with advanced renal cell carcinoma at a university hospital in Japan: before immuno-oncology therapy era","volume":"1","author":"Takayama","year":"2018","journal-title":"J\u00a0Ren Cancer"},{"key":"10.1016\/j.clgc.2019.03.012_bib17","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/bjc.2013.832","article-title":"Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma","volume":"110","author":"Hutson","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2019.03.012_bib18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40266-016-0390-1","article-title":"Efficacy of sunitinib in elderly patients with metastatic renal cell carcinoma: data from real-world clinical practice","volume":"33","author":"Poprach","year":"2016","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clgc.2019.03.012_bib19","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study","volume":"32","author":"Escudier","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.03.012_bib20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jgo.2013.04.004","article-title":"Sorafenib and sunitinib for elderly patients with renal cell carcinoma","volume":"4","author":"Derbel Miled","year":"2013","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.clgc.2019.03.012_bib21","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.03.012_bib22","first-page":"13","article-title":"Moving beyond Karnofsky and ECOG performance status assessments with new technologies","volume":"2016","author":"Kelly","year":"2016","journal-title":"J\u00a0Oncol"},{"key":"10.1016\/j.clgc.2019.03.012_bib23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bjhh.2015.03.007","article-title":"Limitations of performance status assessment in elderly with acute myeloid leukemia","volume":"37","author":"Carbonell","year":"2015","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.clgc.2019.03.012_bib24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"key":"10.1016\/j.clgc.2019.03.012_bib25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.pcan.4500889","article-title":"The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting","volume":"9","author":"Kastner","year":"2006","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2019.03.012_bib26","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1002\/cncr.23462","article-title":"Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer","volume":"112","author":"Koppie","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.03.012_bib27","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.euf.2017.10.010","article-title":"Comprehensive geriatric assessment in the older adult with cancer: a review","volume":"3","author":"Hernandez Torres","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2019.03.012_bib28","doi-asserted-by":"crossref","first-page":"d6553","DOI":"10.1136\/bmj.d6553","article-title":"Comprehensive geriatric assessment for older adults admitted to hospital: meta-analysis of randomised controlled trials","volume":"343","author":"Ellis","year":"2011","journal-title":"BMJ"},{"issue":"15 suppl","key":"10.1016\/j.clgc.2019.03.012_bib29","doi-asserted-by":"crossref","first-page":"e15506","DOI":"10.1200\/jco.2013.31.15_suppl.e15506","article-title":"Safety and activity of sunitinib in elderly patients (75 years or more) with metastatic renal cell carcinoma: results of retrospective study in Paoli-Calmettes Cancer Institute in France","volume":"31","author":"Boulaamane","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.03.012_bib30","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","article-title":"The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer","volume":"88","author":"Guthrie","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2019.03.012_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2016.10.001","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: a proposal of the modified-IMDC risk model","volume":"35","author":"Tanaka","year":"2017","journal-title":"Urol Oncol"},{"issue":"6 suppl","key":"10.1016\/j.clgc.2019.03.012_bib32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1200\/JCO.2017.35.6_suppl.525","article-title":"Analysis of predictive clinical markers of outcome in patients with metastatic clear-cell renal cell carcinoma (mRCC) treated with tyrosine-kinases inhibitors (TKI) in first line: s C Camargo Cancer Center experience","volume":"35","author":"Ferreira","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.03.012_bib33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1155\/2017\/1506824","article-title":"Dynamics of neutrophils-to-lymphocyte ratio predict outcomes of PD-1\/PD-L1 blockade","volume":"2017","author":"Moschetta","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.clgc.2019.03.012_bib34","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1016\/j.clgc.2018.01.010","article-title":"Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and C-reactive protein as new and simple prognostic factors in patients with metastatic renal cell cancer treated with tyrosine kinase inhibitors: a systemic review and meta-analysis","volume":"16","author":"Semeniuk-Wojta\u015b","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.03.012_bib35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4143\/crt.2017.033","article-title":"Incorporating neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in place of neutrophil count and platelet count improves prognostic accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium model","volume":"50","author":"Chrom","year":"2018","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.clgc.2019.03.012_bib36","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2548::AID-CNCR21>3.0.CO;2-4","article-title":"Prognostic factors for survival in patients with brain metastases from renal cell carcinoma","volume":"83","author":"Culine","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.03.012_bib37","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/j.1349-7006.2012.02351.x","article-title":"A\u00a0new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma","volume":"103","author":"Shinohara","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clgc.2019.03.012_bib38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1634\/theoncologist.2011-0227","article-title":"Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies","volume":"17","author":"Shuch","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2019.03.012_bib39","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/annonc\/mdm184","article-title":"Hypertension as a predictive factor of sunitinib activity","volume":"18","author":"Rixe","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.03.012_bib40","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1158\/1078-0432.CCR-10-2806","article-title":"Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors","volume":"17","author":"Rini","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2019.03.012_bib41","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejca.2015.10.006","article-title":"Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced\/metastatic renal cell carcinoma?","volume":"53","author":"Goldstein","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.03.012_bib42","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1464-410X.2010.09569.x","article-title":"Age-related properties of the tumour vasculature in renal cell carcinoma","volume":"107","author":"Meehan","year":"2011","journal-title":"BJU Int"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319301041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319301041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:32:26Z","timestamp":1761564746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767319301041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1558767319301041"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.03.012","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}